|
|
|
|
|
My Recent Searches
|
|
|
|
|
|
|
|
$0.00 0.00 (0.00%) as of 4:30 Tue 11/30
|
|
Download |
|
|
|
|
Exchange: |
N/A |
Security
Type: |
N/A |
Shares
Out: |
36,910,000 |
Market
Cap: |
N/A |
Last
Volume: |
0 |
Avg
Vol: |
0 |
52
Week Range: |
$ - $ |
|
Level
I Sector: |
N/A |
Level
II Sector: |
N/A |
Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
Insider 3 Months : - |
Insider 6 Months : - |
Insider 3/6 Months : - |
|
Guru Rank Number : - |
Guru Rank Value : - |
Guru Occurances : - |
|
|
|
|
|
|
|
Company Profile Akouos is a genetic medicine company, engaged in developing gene therapies to restore, improve, and preserve physiologic hearing for individuals who live with disabling hearing loss. Co. has a genetic medicine platform that incorporates a proprietary vector library consisting of variants of a small virus used in gene therapy, known as adeno-associated virus, and a delivery approach. Co. is developing its product candidate, AK-OTOF, a gene therapy for the treatment of hearing loss due to mutations in the OTOF gene; expansion of its pipeline to include programs focused on other monogenic conditions as well as inner ear conditions of etiology, such as AK-antiVEGF for vestibular schwannoma.
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
3m +/-:
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
Actions:
|
|
|
B |
Buy |
S |
Sell |
OE |
Option
Exercised |
A |
Acquired |
D |
Disposed |
AB |
Automatic
Buy |
AS |
Automatic
Sell |
IO |
Initial
Ownership |
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
|
|
Summary (Direct Transactions Only) |
3 Months |
6 Months |
12 Months |
24 Months |
Total Shares Bought |
0 |
0 |
0 |
29,992,668 |
Total Buy Value |
$0 |
$0 |
$0 |
$374,908,350 |
Total People Bought |
0 |
0 |
0 |
1 |
Total Buy Transactions |
0 |
0 |
0 |
1 |
Total Shares Sold |
0 |
0 |
0 |
0 |
Total Sell Value |
$0 |
$0 |
$0 |
$0 |
Total People Sold |
0 |
0 |
0 |
0 |
Total Sell Transactions |
0 |
0 |
0 |
0 |
End Date |
2024-01-28 |
2023-10-27 |
2023-04-28 |
2022-04-28 |
|
Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
Sandell Scott D |
10% Owner |
|
2022-11-30 |
4 |
D |
$0.00 |
$0 |
I/I |
(4,294,207) |
0 |
|
- |
|
Simons Emmanuel |
Chief Executive Officer |
|
2022-11-30 |
4 |
D |
$0.00 |
$0 |
D/D |
(272,582) |
0 |
|
- |
|
Walker Paul Edward |
10% Owner |
|
2022-11-30 |
4 |
D |
$0.00 |
$0 |
I/I |
(4,294,207) |
0 |
|
- |
|
Florence Anthony A. Jr. |
10% Owner |
|
2022-11-30 |
4 |
D |
$0.00 |
$0 |
I/I |
(4,294,207) |
0 |
|
- |
|
Baskett Forest |
10% Owner |
|
2022-11-30 |
4 |
D |
$0.00 |
$0 |
I/I |
(4,294,207) |
0 |
|
- |
|
Mckenna Michael John |
Chief Medical Officer |
|
2022-11-30 |
4 |
D |
$0.00 |
$0 |
D/D |
(82,385) |
0 |
|
- |
|
Wellman Jennifer Anne |
CHIEF OPERATING OFFICER |
|
2022-11-30 |
4 |
D |
$0.00 |
$0 |
D/D |
(12,338) |
0 |
|
- |
|
Sonsini Peter W. |
10% Owner |
|
2022-11-30 |
4 |
D |
$0.00 |
$0 |
I/I |
(4,294,207) |
0 |
|
- |
|
Parmar Kush |
Director |
|
2022-11-30 |
4 |
D |
$0.00 |
$0 |
I/I |
(4,135,786) |
0 |
|
- |
|
Chang Carmen |
10% Owner |
|
2022-11-30 |
4 |
D |
$0.00 |
$0 |
I/I |
(4,294,207) |
0 |
|
- |
|
Schwab Andrew J. |
10% Owner |
|
2022-11-30 |
4 |
D |
$0.00 |
$0 |
I/I |
(4,135,786) |
0 |
|
- |
|
Preston Heather |
Director |
|
2022-11-30 |
4 |
D |
$0.00 |
$0 |
D/D |
(5,882) |
0 |
|
- |
|
Nea 16 Gp, Llc |
10% Owner |
|
2022-11-30 |
4 |
D |
$0.00 |
$0 |
D/D |
(4,294,207) |
0 |
|
- |
|
Tzianabos Arthur |
Director |
|
2022-11-30 |
4 |
D |
$0.00 |
$0 |
D/D |
(26,930) |
0 |
|
- |
|
Makhzoumi Mohamad |
10% Owner |
|
2022-11-30 |
4 |
D |
$0.00 |
$0 |
I/I |
(4,294,207) |
0 |
|
- |
|
Behbahani Ali |
10% Owner |
|
2022-11-30 |
4 |
D |
$0.00 |
$0 |
I/I |
(4,294,207) |
0 |
|
- |
|
Lilly Eli & Co |
10% Owner |
|
2022-11-30 |
4 |
B |
$12.50 |
$374,908,350 |
D/D |
29,992,668 |
100 |
2.45 |
- |
|
Schwab Andrew J. |
10% Owner |
|
2020-12-29 |
4 |
S |
$18.00 |
$8,460,000 |
I/I |
(470,000) |
982,453 |
|
- |
|
Parmar Kush |
Director |
|
2020-12-29 |
4 |
S |
$18.00 |
$8,460,000 |
I/I |
(470,000) |
982,453 |
|
- |
|
Wellman Jennifer Anne |
CHIEF OPERATING OFFICER |
|
2020-10-01 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
12,338 |
|
- |
|
Novartis Ag |
Former 10% Owner |
|
2020-06-30 |
4 |
B |
$17.00 |
$2,125,000 |
I/I |
125,000 |
1,181,258 |
0.01 |
- |
|
Novartis Ag |
Former 10% Owner |
|
2020-06-30 |
4 |
A |
$0.00 |
$0 |
I/I |
1,056,258 |
1,056,258 |
|
- |
|
Parmar Kush |
Director |
|
2020-06-30 |
4 |
B |
$17.00 |
$4,999,989 |
I/I |
294,117 |
1,094,101 |
2.25 |
- |
|
Parmar Kush |
Director |
|
2020-06-30 |
4 |
A |
$0.00 |
$0 |
I/I |
4,311,667 |
799,984 |
|
- |
|
Schwab Andrew J. |
10% Owner |
|
2020-06-30 |
4 |
B |
$17.00 |
$4,999,989 |
I/I |
294,117 |
1,094,101 |
1.5 |
- |
|
69 Records found
|
|
Page 1 of 3 |
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Acquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|